Glofitamab Shows High Response Rates in Refractory Aggressive B-Cell Lymphoma

Managing patients with relapsed or refractory aggressive B-cell lymphomas remains a significant clinical challenge, as those who fail multiple lines of therapy often face a poor prognosis [1]. While chimeric antigen receptor (CAR) T-cell therapy has improved outcomes, approximately 50% of patients are ineligible for such intensive cellular interventions due to comorbidities or rapid disease progression [2, 3]. Bispecific antibodies (therapeutic proteins that simultaneously bind CD3 on T-cells and CD20 on malignant B-cells to induce targeted cytotoxicity) such as glofitamab and epcoritamab have emerged as accessible, off-the-shelf alternatives [4, 5]. Despite high response rates in pivotal clinical trials, real-world data are needed to understand how these agents perform in unselected populations, particularly those with prior CAR T-cell exposure or specific immunologic profiles [6, 7, 8]. A recent observational study now offers insights into the efficacy and safety of glofitamab in a diverse clinical cohort where only 16% of patients would have met traditional trial inclusion criteria [6].